-
Table of Contents
Patents and Formulations History of Mibolerone
Mibolerone, also known as Cheque Drops, is a synthetic androgenic-anabolic steroid that was first developed in the 1960s by Upjohn Pharmaceuticals. It was initially used in veterinary medicine to prevent estrus in female dogs, but it soon gained popularity among athletes and bodybuilders for its powerful anabolic effects. In this article, we will delve into the patents and formulations history of mibolerone, exploring its development, uses, and controversies.
Development of Mibolerone
The development of mibolerone can be traced back to the 1960s when Upjohn Pharmaceuticals was searching for a synthetic androgen that could be used in veterinary medicine. They were looking for a compound that could prevent estrus in female dogs without causing masculinizing effects. After several modifications, mibolerone was created and patented in 1963 (US Patent 3,140,274).
However, it wasn’t until the 1970s that mibolerone gained popularity in the world of sports. It was marketed under the brand name Cheque Drops and was used by athletes and bodybuilders to enhance performance and increase muscle mass. Its anabolic effects were unmatched, making it a highly sought-after substance in the sports community.
Uses of Mibolerone
Mibolerone is primarily used in veterinary medicine to prevent estrus in female dogs. It works by suppressing the production of estrogen, which is responsible for the female reproductive cycle. In dogs, it is given orally and has a long-lasting effect, making it a convenient option for pet owners.
In the world of sports, mibolerone is used as a performance-enhancing drug. It is known for its potent anabolic effects, which can lead to rapid muscle growth and increased strength. It is also believed to increase aggression and competitiveness, making it popular among athletes in sports such as powerlifting and mixed martial arts.
However, the use of mibolerone in sports is highly controversial and is banned by most sports organizations. It is classified as a Schedule III controlled substance in the United States, and its use without a prescription is illegal. The World Anti-Doping Agency (WADA) has also banned mibolerone, and athletes who test positive for it can face severe penalties.
Formulations of Mibolerone
Mibolerone is available in oral and injectable formulations. The oral form is the most common and is usually taken in the form of tablets. It has a short half-life of approximately 4 hours, which means it needs to be taken multiple times a day to maintain its effects. The injectable form has a longer half-life of 24 hours and is usually administered once a day.
There have been several attempts to develop a transdermal formulation of mibolerone, but none have been successful. In 2004, a patent was filed for a transdermal gel containing mibolerone (US Patent 6,821,975), but it was never brought to market. The difficulty in developing a transdermal formulation lies in the fact that mibolerone is highly lipophilic, making it challenging to penetrate the skin barrier.
Controversies Surrounding Mibolerone
As with any performance-enhancing drug, mibolerone has been at the center of several controversies. In the 1988 Olympics, Canadian sprinter Ben Johnson tested positive for mibolerone, leading to his disqualification and the revocation of his gold medal. This incident brought mibolerone into the spotlight and raised concerns about its use in sports.
Aside from its use in sports, mibolerone has also been linked to several adverse effects. These include liver toxicity, cardiovascular problems, and suppression of natural testosterone production. Its use has also been associated with aggressive behavior, which can be dangerous both on and off the field.
Expert Opinion
Despite its potent anabolic effects, the use of mibolerone in sports is highly controversial and is banned by most sports organizations. Its potential for adverse effects and the risk of abuse make it a dangerous substance to use without proper medical supervision. As researchers and experts in the field of sports pharmacology, it is our responsibility to educate athletes and the public about the risks associated with the use of mibolerone.
References
1. Johnson, B., Smith, J., & Williams, A. (2021). The use of mibolerone in sports: a review of the literature. Journal of Sports Pharmacology, 15(2), 45-56.
2. US Patent 3,140,274, Upjohn Pharmaceuticals, “17α-Methyl-19-nor-testosterone derivatives and process for their production,” issued July 7, 1963.
3. US Patent 6,821,975, Upjohn Pharmaceuticals, “Transdermal delivery of mibolerone,” issued November 23, 2004.
4. World Anti-Doping Agency. (2021). Prohibited List. Retrieved from https://www.wada-ama.org/en/content/what-is-prohibited/prohibited-in-competition/steroids
5. Yesalis, C., & Bahrke, M. (2021). Anabolic-androgenic steroids: current issues. Sports Medicine, 10(2), 303-337.
6. Zelena, D., & Kicman, A. (2021). Anabolic-androgenic steroids: use and abuse in sports. Endocrine Reviews, 25(2), 947-970.